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Rap2B promotes proliferation, 
migration, and invasion of human 
breast cancer through calcium-
related ERK1/2 signaling pathway
Jiehui Di1,4,*, Hui Huang1,3,*, Debao Qu1,*, Juangjuan Tang1, Wenjia Cao1, Zheng Lu1, 
Qian Cheng1, Jing Yang1, Jin Bai1, Yanping Zhang2,4 & Junnian Zheng2
Rap2B, a member of GTP-binding proteins, is widely upregulated in many types of tumors and 
promotes migration and invasion of human suprarenal epithelioma. However, the function of Rap2B 
in breast cancer is unknown. Expression of Rap2B was examined in breast cancer cell lines and 
human normal breast cell line using Western blot analysis. Using the CCK-8 cell proliferation assay, 
cell cycle analysis, and transwell migration assay, we also elucidated the role of Rap2B in breast 
cancer cell proliferation, migration, and invasion. Results showed that the expression of Rap2B is 
higher in tumor cells than in normal cells. Flow cytometry and Western blot analysis revealed that 
Rap2B elevates the intracellular calcium level and further promotes extracellular signal-related kinase 
(ERK) 1/2 phosphorylation. By contrast, calcium chelator BAPTM/AM and MEK inhibitor (U0126) 
can reverse Rap2B-induced ERK1/2 phosphorylation. Furthermore, Rap2B knockdown inhibits cell 
proliferation, migration, and invasion abilities via calcium related-ERK1/2 signaling. In addition, 
overexpression of Rap2B promotes cell proliferation, migration and invasion abilities, which could 
be neutralized by BAPTM/AM and U0126. Taken together, these findings shed light on Rap2B as a 
therapeutic target for breast cancer.
Breast cancer is by far the most frequently diagnosed cancer and the second leading cause of cancer death 
in women worldwide1. Unfortunately, for all breast cancer patients, the long-term recurrent rates can be 
as high as 40%, of which 10%–20% are local and 60%–70% are distant metastases2. Tumor metastasis is a 
complex process mainly involving cell proliferation, migration, invasion, adhesion and vessel formation3. 
Therefore, unraveling the molecular mechanisms underlying breast cancer progression and metastasis 
would reveal lead molecules for targeted therapy4.
The Rap family of small GTP-binding proteins is composed of five members, namely, Rap1A, Rap1B, 
Rap2A, Rap2B and Rap2C, which are grouped into two subfamilies, namely, Rap1 and Rap25. Studies 
have indicated that Ras family members are implicated in a range of biological functions in human cells, 
such as signal transduction, proliferation and migration6,7. Rap1 has elicited much stronger interest than 
the highly homologous Rap2 proteins; however, the role of Rap1 in carcinogenesis remains controversial. 
On one hand, aberrant activation of Rap1 leads to increased cancer cell proliferation and carcinogen-
esis6,8; on the other hand, inactivation of the Rap1 promotes invasion of osteosarcoma cells9. Although 
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the effector region of Rap2 proteins differs from that of Rap1 proteins by just one residue, the exact role 
of Rap2 in carcinogenesis remains obscure.
Rap2B was first discovered from platelet cDNA library in the early 1990s10,11. Rap2B, being one of the 
members of the Ras superfamily, was predominantly upregulated in many types of tumors12. Renewed 
interest in Rap2B as a novel candidate oncogene in lung cancer rapidly mounted. Increased level of 
Rap2B expression is observed in lung cancer, and is involved in tumorigenesis through activation of the 
NF-kappa B pathway13. Subsequently, foci formation assay and wound-healing assay revealed that the 
extrinsic expression of Rap2B could transform NIH3T3 cell14. In addition, Rap2B as a novel p53 target 
participates in p53-mediated pro-survival function, which also raises the possibility that targeting Rap2B 
could sensitize tumor cells to apoptosis in response to DNA damage12. A recent study has reported 
that miR-342-3p targets Rap2B to suppress cell proliferation, migration, and invasion of non-small cell 
lung cancer15. Previously, we have demonstrated that Rap2B promotes migration and invasion of human 
suprarenal epithelioma. However, the expression and function of Rap2B have not been fully elucidated 
in the development of human breast cancer.
In the current study, we showed that the expression level of Rap2B was higher in breast cancer 
cells than in normal cells. Furthermore, Rap2B could upregulate the intracellular calcium level and the 
phosphorylation level of extracellular signal-related kinase (ERK) 1/2, which could be weakened by the 
cell-permeable calcium chelator BAPTM/AM and the specific inhibitors of MEK1/2 (U0126). Moreover, 
we also identified that Rap2B increased cell proliferation, migration and invasion abilities by upregulat-
ing calcium-related ERK1/2 signaling pathway. Our study may provide a potential therapeutic target for 
human breast cancer.
Results
Rap2B expression is increased in breast cancer. To investigate whether different expressions of 
Rap2B exist in breast cancer development, Western blot assay was performed using breast cancer cell 
lines and human normal breast epithelial cell line, MCF10A. It was clear that the breast cancer cell lines 
had significant increase expression as compared with MCF10A (Fig.  1A). These results showed that 
Rap2B is upregulated in breast cancer. Small interfering RNA (siRNA) was used to knockdown Rap2B 
expression in both Bcap-37 and MDA-MB-231 cells. Forty-eight hours after transfection, Rap2B protein 
was drastically decreased (Fig.  1B). In addition, pcDNA3.1-Myc3 control or pcDNA3.1-Myc3-Rap2B 
plasmids were transiently transfected into both cell lines. Twenty-four hours after transfection, Rap2B 
protein was significantly overexpressed (Fig. 1C).
Rap2B regulates cell proliferation in breast cancer cells. To further validate whether Rap2B affects 
carcinoma cell survival, cell viability was determined by CCK-8 cell proliferation assay. Knockdown of 
Rap2B inhibited cell growth in both Bcap-37 and MDA-MB-231 cells compared with the cells transfected 
with the negative control siRNA (Fig.  2A). At the same time, our data demonstrated that overexpres-
sion of Rap2B increased cellular growth in both breast cancer cell lines (Fig. 2B). To evaluate whether 
the reduced cell proliferation resulting from Rap2B knockdown was due to cell cycle arrest, we subse-
quently performed flow cytometry analysis to determine the role of Rap2B in cell cycle distribution. As 
expected, knockdown or restoration of Rap2B has no effect on cell cycle distribution of breast cancer 
cells (Fig. 2C,D). The data above indicated that Rap2B could promote cell proliferation, but has no effect 
on the cell cycle.
Rap2B induces calcium-dependent phosphorylation of ERK. Stope et al. reported that Rap2B 
directly interacts with and induces activation of PLCε 16. PLCε catalyzes the hydrolysis of phosphati-
dylinositol 4, 5-bisphosphate, and strongly increases diacylglycerol (DAG) accumulation and inositol 
1,4,5-trisphosphate (IP3) formation. Subsequently, IP3 triggers calcium mobilization resulting in rapid 
increase in intracellular calcium concentrations. Calcium ion is an intracellular second messenger that 
regulates numerous biological processes17,18. Thus, we performed flow cytometry to determine the intra-
cellular calcium level in breast cancer cells. Data revealed that intracellular calcium level is suppressed 
after knockdown of Rap2B in Bcap-37 and MDA-MB-231 cells, whereas overexpression of Rap2B upreg-
ulates intracellular calcium level (Fig.  3A,B). Then we performed Western blot analysis to detect the 
total expression and phosphorylation levels of ERK1/2 in breast cancer cells, which is an important 
downstream substrate for calcium ions. After transfection and starvation, serum was used to increase 
phosphorylation of ERK1/2 for 30 min in both Bcap-37 and MDA-MB-231 cells. Inhibition of ERK1/2 
phosphorylation was observed after Rap2B knockdown in breast cancer cells (Fig. 3C), whereas the total 
expression of ERK1/2 did not change. Meanwhile, our data also showed that the phosphorylation level of 
ERK1/2 increased in both cell lines transfected with Rap2B (Fig. 3D–F). In addition, the cell-permeable 
calcium chelator BAPTM/AM and the specific inhibitor of MEK1/2 (U0126) were used to study their 
effects in Rap2B-mediated signaling. The upregulation of phosphorylated ERK1/2 induced by Rap2B 
overexpression was aborted by U0126 and BAPTM/AM in both cell lines (Fig. 3D,E). However, Rap2B 
expression did not change after treatment with those inhibitors (Fig. 3D–F). These results indicated that 
Rap2B is an upstream regulator of the calcium-related ERK1/2 signaling pathway.
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Figure 1. Protein expression level of Rap2B in breast cancer cell lines. (A) Western blot analysis of Rap2B 
expression in MCF-10A, MDA-MB-231, Bcap-37, SK-BR-3 and MCF-7 group with Rap2B antibody. β -actin 
served as loading control. The intensity of Rap2B was quantified by densitometry (software: Image J, NIH). 
(B) Western blot analysis of Rap2B in the Rap2B knockdown and control siRNA group for both Bcap-37 
and MDA-MB-231 cell lines. The intensity of Rap2B was quantified by densitometry. (C) Western blot 
analysis to measure the protein levels of Rap2B in breast cancer cells transfected with Rap2B plasmids and 
pcDNA3.1-Myc3 plasmids. The intensity of Rap2B was quantified by densitometry. All experiments were 
carried out in triplicate. Data are presented as mean ± SD (n = 3). **P < 0.01 in comparison with respective 
group.
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Figure 2. Effect of Rap2B on cell proliferation of breast cancer cells. (A) CCK-8 cell proliferation assay 
after Rap2B knockdown in Bcap-37 and MDA-MB-231 cells. (B) CCK-8 cell proliferation assay after Rap2B 
overexpressed in breast cancer cells. (C) Influence of Rap2B gene silencing on the cell cycle of breast cancer 
cells. The percentage of G1 population cells was measured by flow cytometry after Rap2B knockdown in 
breast cancer cells. (D) Influence of Rap2B gene overexpression on cell cycle analysis of breast cancer cells. 
The percentage of cells at G1 stage was calculated using ModFit LT 3.0 software. All experiments were 
carried out in triplicate. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01 in comparison with 
respective group.
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Figure 3. Rap2B can increase the intracelluar calcium level and induce ERK1/2 phosphorylation.  
(A) Rap2B siRNA could decrease intracelluar calcium level in Bcap-37 and MDA-MB-231 cell lines, as 
measured by a flow cytometer. (B) Rap2B overexpression increased intracelluar calcium level in breast cancer 
cells. (C) After breast cancer cells were transfected and starved, some cells were treated with 10% FBS and 
some were not. Western blot analysis of the protein levels of Rap2B, p-ERK, and ERK in Rap2B knockdown 
and control siRNA group for both cell lines. (D) After transfection and starvation, cells were incubated in 
the presence or absence of U0126 for 30 min. Then, some cells were treated with 10% FBS and some were 
not. Western blot analysis of the protein levels of Rap2B, p-ERK, and ERK in Rap2B overexpression and 
control group for both cell lines. (E) After transfection and starvation, cells were incubated in the presence 
or absence of BAPTA/AM for 30 min. Then, some cells were treated with 10% FBS. Western blot analysis of 
the protein levels of Rap2B, p-ERK, and ERK in Rap2B over-expression and control group for both cell lines. 
All experiments were carried out in triplicate. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01 
in comparison to respective group, #P < 0.05, ##P < 0.01 in comparison with respective 10% FBS-untreated 
group, and &P < 0.05, &&P < 0.01 in comparison with respective inhibitor-untreated group.
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Rap2B could promote cell migration and invasion via Rap2B-calcium-ERK1/2 signaling path-
way. Rap2B could upregulate cell proliferation and induce calcium-dependent phosphorylation of ERK, 
so we sought to determine whether Rap2B could affect cell migration and invasion. Wound-healing assay, 
migration assay and matrigel invasion assay were carried out in breast cancer cells. In cell wound-healing 
assay, 10 μ g/ml mitomycin C was incubated for 2 h prior to the scratch assay, which inhibited mito-
sis of the cells and allowed us to distinguish migration from proliferation19–22. Data showed that the 
wound-healing rate in Bcap-37 and MDA-MB-231 cells with Rap2B knockdown is slower than that in 
control siRNA group (Fig.  4A). In cell migration assay, we found that Rap2B knockdown suppresses 
cell migration ability by 71% and 58% in Bcap-37 and MDA-MB-231 cells, respectively (Fig. 4B). In cell 
invasion assay, silencing of Rap2B inhibits cell invasive ability of Bcap-37 and MDA-MB-231 cells by 50% 
and 73%, respectively (Fig. 4C). Meanwhile, restoration of Rap2B promotes cell migration and invasion 
in breast cancer cells in vitro (Fig.  5A–C). Collectively, results illustrate that Rap2B could enhance the 
migration and invasion of Bcap-37 and MDA-MB-231 cells in vitro.
Thus, we inferred that Rap2B promotes migration and invasion of breast cancer cells via calcium 
related-ERK1/2 signaling pathway. To further validate our assumption, we investigated the involvement 
of calcium and ERK1/2 on the Rap2B-induced migratory effect in migration and invasion assays using 
specific pathway inhibitors, namely, BAPTM/AM (30 μ M) and U0126 (10 μ M), respectively. As expected, 
both pharmacological inhibitors reduced Rap2B-induced effect on cell migration and invasion of breast 
cancer cells (Fig. 5A–C). These data collectively showed that Rap2B overexpression increases the level of 
calcium, which subsequently mediates calcium related-ERK1/2 signaling pathway activation, and finally 
leads to breast cancer cell migration and invasion.
Discussion
Rap2B gene was originally cloned from the cDNA library of human platelets and is located at 3q25.2 
of human chromosome, which is a hotspot of cancer research23,24. Rap2B protein is a member of the 
Ras superfamily of small GTPases. Studies have shown that Ras gene mutations or overexpressions are 
involved in oncogenesis of a variety of human tumors and in poor prognostic significance for survival25. 
Aberrant activation of Rap is implicated in processes such as cell cycle control, migration and invasion 
of cancer cells6,8,26,27. Rap2 protein expression has been detected to be several folds higher in human 
thyroid cancer cells28. Notably, Rap2 reportedly induces cytoskeleton rearrangements and promotes cell 
rounding and migration29,30. Moreover, Rap2A is involved in tumor formation and malignant progression 
in human prostate and follicular thyroid cancers31,32. A new study has shown that Rap2B supports the 
oncogenic status and acts as an oncogene in human cancers12,15. In this study, our results demonstrated 
that Rap2B expression is predominantly increased in breast cancer cell lines (Fig. 1A), which is consistent 
with the result of our previous study indicating that the levels of Rap2B expression are all significantly 
higher in tumor tissues than those in adjacent, normal renal tissues33. Taken together, we infer that 
Rap2B might play an important role in the development of breast cancer.
Schmidt et al. first reported that Rap2B stimulates PLCε and induces calcium increase34,35. Active 
Rap2B strongly enhances the formation of diacylglycerol [DAG] and inositol 1,4,5-trisphosphate [IP3], 
and the subsequent activation of protein kinase C isoforms and Ca2+ release from intracellular stores36. 
Our present study also confirmed that intracellular calcium level is suppressed after knockdown of 
Rap2B, whereas it is enhanced by Rap2B overexpression (Fig. 3A,B). However, the mechanism through 
which Rap2B regulates calcium release in breast cancer cells remains to be elucidated. Calcium could 
transfer the signal to the downstream signaling molecules leading to ERK1/2 activation. ERK, which is 
a member of the mitogen-activated protein kinase pathway, is reported to induce cell-cycle signaling to 
promote cell proliferation and differentiation37. We found that the ability of cell proliferation is decreased 
after Rap2B knockdown in breast cancer cells, and high proliferative activity of tumor cells is associ-
ated with increased cell-cycle transition38. Our data showed that knockdown of Rap2B does not arrest 
cell-cycle progression at the G1 to S transition (Fig. 2C,D), which is similar to the findings of Zhang12. 
Our data also showed that increased Rap2B enhances the expression of phosphorylated ERK1/2, whereas 
the total levels remain unchanged (Fig.  3D). At the same time, ERK1/2 phosphorylation induced by 
Rap2B was blocked by the cell-permeable calcium chelator (BAPTM/AM) and by the specific inhibitor 
of ERK1/2 (U0126) (Fig. 3D–F). However, Rap2B expression did not change after treatment with those 
inhibitors (Fig. 3D–F). These results suggested that Rap2B should be an upstream factor modulating the 
Ca2+-related ERK1/2 signaling pathways in breast cancer.
Calcium is an ubiquitous second messenger that is known to be involved in several fundamental 
physiological functions, such as cell cycle control, survival, migration, and gene expressions39,40. ERK, 
which is a known effector for cytoskeletal regulation, promotes epithelial-mesenchymal transition and 
facilitates cell migration, such as of pancreatic cancer cells41. Given that Rap2B is an upstream target 
of the Ca2+-related ERK1/2 signaling pathway in cancer cells, Rap2B possibly contributes to impor-
tant events during tumor progression, such as cell proliferation, migration, invasion, and metastasis42,43. 
Tissue invasion and metastasis is an exceedingly complex process that represents one of the six initial 
cancer hallmarks44. Our present study first demonstrated that significant promotions of invasion and 
migration by overexpression of Rap2B exist in breast cancer cell lines (Fig.  5). As expected, migration 
and invasion abilities can be suppressed by inhibitors BAPTM/AM and U0126, respectively. This result is 
similar to that of Wang et al.45 which suggests that calcium-related ERK1/2 signaling positively mediates 
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Figure 4. Knockdown of Rap2B inhibits breast cancer cell migration and invasion abilities . (A) Wound-
healing assay was performed after Rap2B knockdown in Bcap-37 and MDA-MB-231 cell lines. (B) Cell 
migration assay was carried out after Rap2B knockdown in breast cancer cells. (C) A matrigel cell invasion 
assay was carried out after Rap2B knockdown in breast cancer cells. All experiments were carried out in 
triplicate. Data are presented as mean ± SD (n = 3). **P < 0.01 in comparison with respective group.
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Rap2B-stimulated cell growth, migration and invasion. Our previously published paper demonstrated 
that Rap2B can promote migration and invasion of human suprarenal epithelioma by increasing MMP-2 
protein expression and activity. We also examined the levels of MMP-2 and MMP-9 in the present study, 
and our data demonstrated that knockdown of Rap2B has no effect on protein expression and enzyme 
activity of MMP-2 and MMP-9.
In summary, our results showed that Rap2B is expressed at high levels in breast cancer cell lines, and 
that Rap2B could induce calcium-dependent phosphorylation of ERK1/2. Furthermore, we demonstrated 
that Rap2B can influence breast cancer cell proliferation, migration, and invasion through elevated 
intracellular calcium level and further promote ERK1/2 phosphorylation, as shown in Fig.  6. Further 
experiments are underway to evaluate the effect of Rap2B on cell migration and invasion by regulating 
Ca2+-related ERK1/2 signaling pathway using an in vivo tumor mouse model, hoping that we can provide 
a useful therapeutic strategy to help restrain the progression of breast cancer.
Materials and Methods
Cell culture and transfection. Human breast carcinoma cell lines (Bcap-37, MDA-MB-231, SK-BR-3 
and MCF-7) and human breast epithelial cell line (MCF10A) were purchased from the Shanghai Institute 
of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Bcap-37 cells were 
grown in RPMI 1640 medium, MDA-MB-231 cells were maintained in L15 medium, and SK-BR-3 and 
Figure 5. Rap2B overexpression promotes breast cancer cell migration and invasion abilities. (A)
Wound-healing assay was performed after reintroduction of Rap2B in Ctrl, Rap2B, Rap2B + BAPTA/AM 
and Rap2B + U0126 group in Bcap-37 and MDA-MB-231 cell lines. Starved cells were incubated with 
30 μ mol/L BAPTA/AM and 10 μ mol/L U0126. (B) Cell migration assay was carried out after overexpression 
of Rap2B in Ctrl, Rap2B, Rap2B+ BAPTA/AM and Rap2B+ U0126 group in breast cancer cells. Starved 
cells were incubated with 30 μ mol/L BAPTA/AM and 10 μ mol/L U0126. (C) A matrigel cell invasion assay 
was carried out after overexpression of Rap2B in Ctrl, Rap2B, Rap2B + BAPTA/AM and Rap2B + U0126 
group in breast cancer cells. Starved cells were incubated with 30 μ mol/L BAPTA/AM and 10 μ mol/L 
U0126. All experiments were carried out in triplicate. Data are presented as mean ± SD (n = 3). **P < 0.01 
in comparison with respective group, and &P < 0.05, &&P < 0.05 in comparison with respective inhibitor-
untreated group.
www.nature.com/scientificreports/
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MCF-7 were cultured in DMEM medium. All these media were supplemented with 10% fetal bovine serum 
(Invitrogen, Shanghai, China). MCF10A cells were cultured in DMEM/F12 medium. Nonspecific control 
siRNA or Rap2B siRNA (Invitrogen, Shanghai, China) was transfected into Bcap-37 and MDA-MB-231 
cells at 50% confluence by siLentFect Lipid Reagent (Bio-Rad, Hercules, CA) according to the man-
ufacturer’s protocol. The pcDNA3-Myc3-control and pcDNA3-Myc3-Rap2B expression plasmids were 
obtained from Dr. Yanping Zhang (The University of North Carolina at Chapel Hill, North Carolina, 
USA). Cells were grown to 90% confluence before being transiently transfected with Rap2B plasmids 
using Lipofectamine 2000 (Invitrogen, Shanghai, China) according to the manufacturer’s protocol.
Western blot analysis. After performing specific treatments, cells were harvested and washed three 
times with PBS. After insoluble debris was pelleted by centrifugation at 15,000 g for 15 min at 4 °C, the 
supernatants were collected and examined for protein concentrations using the bicinchoninic acid (BCA) 
kit (Pierce, USA) according to the manufacturer’s instructions. Proteins were separated by electropho-
resis on SDS-polyacrylamide gel electrophoresis (PAGE) and electro-transferred to nitrocellulose filter 
(NC) membrane. After being blocked for 2 h in 5% bovine serum albumin (BSA), membranes were incu-
bated overnight at 4 °C with the following primary antibodies: anti-Rap2B, anti-p-ERK1/2, anti-ERK1/2 
and anti-β -actin. Membranes were then washed and incubated with secondary antibodies conjugated 
with IRDye 680 or IRDye 800 (Rockland). Fluorescent signals were visualized with Odyssey infrared 
imaging system (Li-COR Lincoln, NE).
Cell proliferation assay. Cellular proliferation was analyzed using cell counting kit-8 (CCK-8) 
(Beyotime, Nantong, China). Bcap-37 cells and MDA-MB-231 cells were seeded at a density of 2 × 103 
per well and 1 × 104 per well in a 96-well culture plate. Cell proliferation was detected at 24, 48, 72, and 
96 h, respectively. Then, 100 μ l serum-free culture medium and 10 μ l CCK-8 solutions were added to each 
well, followed by incubation at 37 °C for 1 h. The optical density at 450 nm was measured on an ELX-800 
spectrometer reader (Bio-Tek Instruments, Winooski, USA).
Cell-cycle analysis. After transfection, cells were harvested and washed with PBS three times. Then, 
the cells were fixed with 70% cold ethanol at − 20 °C overnight. Cells were resuspended in 1 ml DNA 
staining solution and incubated for 30 min at room temperature. DNA content of cells was quantified 
by FACScan flow cytometer (BD Biosciences, San Jose, CA, USA). Data on cell cycle distribution were 
analyzed using ModFit LT 3.0 software.
Measurement of intracellular calcium. The cytoplasmic calcium concentration in breast carcinoma 
cells was measured using the Ca2+-sensitive fluorescent dye Furo 3-AM (Dojindo Laboratories, Japan). 
Figure 6. A schematic diagram illustrating the proposed Rap2B-induced calcium-related ERK1/2 
signaling pathway involved in breast cancer cell proliferation, migration, and invasion. Rap2B increases 
the intracellular calcium level, which subsequently phosphorylates the downstream target of ERK1/2, thereby 
promoting breast cancer cell proliferation, migration, and invasion in vitro. Together, it will support the 
novel notion that Rap2B promotes tumor cell proliferation, migration, and invasion via calcium-related 
ERK1/2 signaling pathway.
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After transfection, cells were washed with HBSS three times and incubated in 1000 μ l HBSS containing 
5 μ l Fluo 3-AM for 1 h at 37 °C in the dark. Then, cells were washed with HBSS three times, harvested, 
and analyzed using a FACSCanto flow cytometer (BD Biosciences, San Jose, CA).
Wound-healing assay. For wound-healing assay, cells were seeded into six-well plates in culture 
medium and were transfected with either siRNA or plasmids. The cells were starved with serum-free 
medium overnight and incubated with 10 μ g/ml mitomycin C (Roche, Germany) for 2 h prior to the 
scratch assay. A scratch was drawn at the center of the well, and then the wounded monolayer was photo-
graphed at the indicated time via fluorescent microscopy (Ti-U, Nikon, Japan) with ×100 magnification. 
Wound-healing percentage of the cells was determined by the ratio of healing width at each time point 
to the wound width at 0 h.
Migration and invasion assay. Cell migration and invasion assay were performed using modi-
fied two-chamber plates with pore size of 8 μ m. For the migration assay, 2 ×104 Bcap-37 and 1.5 ×104 
MDA-MB-231 cells were seeded in serum-free medium in the upper chamber. For the invasion assay, 
3×104 Bcap-37 and 4.5×104 MDA-MB-231 cells were added to the top chamber coated with matrigel 
(BD Biosciences, NJ, USA). To stimulate migration or invasion, complete medium was added to the 
bottom wells. After 12 h or 24 h incubation at 37 °C, cells in the upper chamber were carefully removed 
with a cotton swab and the cells that had traversed the membrane were fixed in methanol and stained 
with Crystal Violet Staining Solution. For quantification, five fields (up, down, median, left, right ×200) 
per filter were counted under a microscope.
Statistical analysis. Values are expressed as mean ± SD. All statistical analyses were carried out using 
SPSS 16.0 software (SPSS). Statistical analysis in treatment groups were assessed by Student’s t-tests. All 
experiments were performed at least three times unless otherwise indicated. P-value < 0.05 was consid-
ered statistically significant.
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